Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia in a Real-World Setting
Key facts
- Who runs it
- Azienda Ospedaliero, Universitaria Pisana
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 31 people enrolled
- Started
- 1 Oct 2023
- Ended
- 30 Jun 2025
- Type of study
- Observational
- Treatments tested
- Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting
- Record updated
- 20 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥ 18 years
- Signed informed consent form
- Diagnosis of chronic insomnia according to DSM-5 criteria, defined as:; Dissatisfaction with sleep quantity or quality, associated with one or more of the following:; Difficulty initiating sleep; Difficulty maintaining sleep (frequent awakenings or trouble returning to sleep); Early morning awakenings with inability to return to sleep; The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, or other important areas of functioning; Sleep difficulties occur despite adequate opportunity and circumstances for sleep; The insomnia is not better explained by or occurring exclusively during other sleep-wake disorders (e.g., narcolepsy, parasomnias, circadian rhythm sleep-wake disorders, breathing-related sleep disorders); The insomnia is not attributable to the physiological effects of a substance (e.g., drug abuse or medication)
- No contraindications to daridorexant use according to the European Medicines Agency (EMA)
Who cannot take part
- Pregnancy
- Breastfeeding
- Withdrawal of informed consent at any time
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The primary objectives of this study is to evaluate the real-world effectiveness of daridorexant 50 mg in improving both subjective (self-report) and objective (actigraphic) sleep parameters in patients with chronic insomnia.
Read full original descriptionShow less
The secondary aims of this study are:
* To compare the effectiveness of daridorexant 50 mg with other guideline-recommended therapies for chronic insomnia in improving sleep parameters and sleep health. * To identify clinical and demographic predictors of response to daridorexant 50 mg, such as age, sex, BMI, duration of insomnia, and treatment regimen (monotherapy vs. add-on). * To monitor changes over time in the symptoms related to comorbid sleep disorders (e.g., OSA, RLS, circadian rhythm disorders) in patients treated with daridorexant 50 mg.
Treatments tested
- Daridorexant 50 mg orally, once daily at bedtime, administered as monotherapy or add-on therapy for chronic insomnia, in a real-world, observational, prospective clinical setting
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Observational Study on the Effectiveness of Daridorexant in Chronic Insomnia Using Subjective and Actigraphic Sleep Measures in a Real-World Setting
- Record updated
- 20 August 2025